Business Wire

IRAP/EUROPEAN-PIRATES

15.10.2020 04:02:06 CEST | Business Wire | Press release

Share
Institute for Rational Drug Policies and European Pirate Party Call on European Commission to Implement Harm Reduction Policies to Help European Citizens Make Positive Lifestyle Choices

A webinar on Citizen Focused Disease Prevention, organised by the Institute for Rational Drug Policies (IRAP) in cooperation with the European Pirates, established that harm reduction policies should be used to help people with a wide range of addictions, including smoking.

“We support the concept of harm reduction. Pirates emphasise the need to focus long-term attention on drug use and addictions,” said Mikuláš Peksa, Czech Green MEP. “We are working on a long-term prevention programme of minimising risks at the national level and at the European level. We must also consider how to minimise the negative impact of government drug policies and laws, and this point of view should also be followed by the European Commission.”

The European Commission currently fails to recognise the potential of harm reduction policies even though there is clear public support for them as shown by the recent Town Hall organised by the Commission on Europe's Beating Cancer Plan. Despite harm reduction being perceived by the Town Hall audience as being extremely important, the Commission still refuses to take harm reduction seriously.

According to Jindrich Voboril, Head of IRAP and former long-term National Anti-Drug Coordinator in the Czech Republic: “We have to consider harm reduction not only as a type of social or health service but as a complex approach that should also be incorporated into law and drug policies.”

Advising how to embrace harm reduction into practice: “One part of it is changing the European Commission’s structure. How can we be effective when illicit drugs are solved with one set of criteria, licit drugs with another and problem gambling is left aside altogether? The current situation does not allow effective solution to drug policies and it is hardly cost-effective. The structure of the Directorate General must be changed and the mandate of the EMCDDA (European Monitoring Centre for Drugs and Drug Addictions) must be strengthened. In the context of the ongoing debate on Europe’s Beating Cancer Plan, it’s time that the European Commission begins to take the concept of harm reduction seriously,” concluded Voboril.

“Harm reduction is a broad concept that can complement other approaches, for example when tackling addiction,” said Kasia Kowalczyk from The Global Public Health Network alongside her colleague David Mackintosh. “Harm Reduction has untapped potential across different areas of public health. It works best through a collaborative approach and engages the beneficiaries of public health services or other interventions.”

During the discussion, Hana Horka from the European Commission’s DG SANTE was not enthusiastic about harmonising approaches to addiction. Ms. Horka, despite endorsing harm reduction policies for drug addiction, did not endorse harm reduction policies for tobacco or alcohol, instead advocating for tax increases and prohibitive measures on tobacco products.

Abstinence should not be regarded as the only option for addicts. The goal of harm reduction policies is to keep people alive, help them to make positive changes in their lives and offer them alternatives that cause less harm.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en

Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release

At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta

Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye